Hepatotoxicity has been described for all antimycotic azoles currently marketed. A possible mechanism involving mitochondrial dysfunction has been postulated for ketoconazole, but not for the other azoles. The aim of the current investigations was to study the toxicity of different azoles in human cell models and to find out mechanisms of their toxicity. In HepG2 cells, posaconazole and ketoconazole were cytotoxic starting at 20 and 50 mM and decreased the cellular ATP content starting at 5 and 10 mM, respectively. In HepaRG cells, cytotoxicity started at 20 and 100 mM for posaconazole and ketoconazole, respectively, and was slightly accentuated by cytochrome P450 3A4 induction with rifampicin and 1A2 with 3-methylcholantrene. Voriconazole and fluconazole were not cytotoxic. In isolated mouse liver mitochondria, ketoconazole impaired membrane potential and complex I activity, whereas the other azoles were not toxic. In HepG2 cells exposed for 24 h, both posaconazole and ketoconazole (but not fluconazole or voriconazole) decreased the mitochondrial membrane potential, impaired the function of enzyme complexes of the electron transport chain, were associated with mitochondrial superoxide accumulation, decreased mitochondrial DNA and induced apoptosis. In HepG2 cells with mitochondrial dysfunction induced by the vitamin B12 antagonist hydroxycobalamin [c-lactam], cytotoxicity and/or ATP depletion was more accentuated than in untreated cells. We conclude that ketoconazole and posaconazole are mitochondrial toxicants starting at concentrations, which can be reached in vivo. Cytotoxicity and ATP depletion are more accentuated in cells with mitochondrial damage, suggesting that preexisting mitochondrial dysfunction is a susceptibility factor for hepatotoxicity associated with these drugs.
A recent review and meta-analysis estimated an overall incidence of 3.6%-4.2% for symptomatic and asymptomatic liver injury in patients treated with ketoconazole (Yan et al., 2013) . The real incidence may even be higher due to underreporting. In comparison to ketoconazole, the frequency of liver injury associated with the newer azole antifungal drugs is less well established, but is probably lower (Kao et al., 2014) .
To date, the exact mechanism of liver toxicity associated with these drugs is not entirely clear. An early study demonstrated cytotoxicity of ketoconazole in cultured rat hepatocytes (Rodriguez and Acosta, 1995) . Later, the same authors showed that the cytotoxic effect of ketoconazole is not only associated with the parent compound, but also with N-deacetyl ketoconazole, the main metabolite of ketoconazole (Rodriguez and Acosta, 1997b) . Furthermore, they also showed that ketoconazole decreased the complex I and II activities of the electron transport chain in isolated rat liver mitochondria, suggesting that mitochondria may play an important role in azoleassociated hepatotoxicity (Rodriguez and Acosta, 1996) .
Because, mechanistic toxicological studies concerning fluconazole, voriconazole, and posaconazole are rare or lacking, our first goal was to study the hepatocellular toxicity of these drugs in comparison to ketoconazole. For that, we used two human hepatoma cell lines, namely HepG2 and HepaRG cells. The second goal was to find out possible mechanisms of hepatotoxicity, with a special focus on mitochondrial toxicity and involvement of metabolites contributing to toxicity. If mitochondrial toxicity were detected, a third aim was to test such substances in a newly created cell model with mitochondrial dysfunction (Haegler et al., 2015) with the assumption that the toxicity would be increased.
MATERIALS AND METHODS
Chemicals. Ketoconazole, posaconazole, voriconazole, and fluconazole were purchased from Sigma-Aldrich (Buchs, Switzerland). Stock solutions were dissolved in DMSO and stored at À20 C. We used control incubations containing 0.1% DMSO and this concentration has been shown not be cytotoxic (Waldhauser et al., 2006) . Hydroxy-cobalamin[c-lactam] (HCCL) was synthesized on request from ReseaChem (Burgdorf, Switzerland). The manufacturer declared a purity of 99% by high-performance liquid chromatography and confirmed the structure by 1 H-NMR analysis. Stock solutions of HCCL were prepared in water and stored at À20 C. All other chemicals used were purchased from Sigma-Aldrich or Fluka (Buchs, Switzerland), except where indicated.
Cell lines and cell culture. Two cell lines were used; HepG2 cells and HepaRG cells. HepG2 cells were provided by ATCC (Manassas, USA) and cultured in low-glucose media. Lowglucose containing medium was prepared with Dulbecco's Modified Eagle Medium (DMEM) containing 1.0 g/l glucose, 4 mM L-glutamine, and 1 mM pyruvate from Invitrogen (Basel, Switzerland). The medium was further supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM GlutaMax, 10 mM HEPES buffer, and non-essential amino acids. HepG2 cells are well suited for investigating cytotoxicity of drugs, in particular for mitochondrial toxicants (Kamalian et al., 2015) . Because, the expression of cytochrome P450 enzymes is low or absent (Berger et al., 2016; Gerets et al., 2012) , they are not suited for studying the formation of metabolites. HepaRG cells were obtained from Dr. Christiane Guguen-Guillouzo (Rennes, France) and cultured as described (Aninat et al., 2006) . In comparison to HepG2 cells, HepaRG cells are better differentiated with a high expression and inducibility of cytochrome P450 enzymes (Berger et al., 2016; Gerets et al., 2012) . Cell culture supplements were all purchased from GIBCO (Paisley, UK). We kept the cells at 37 C in a humidified 5% CO 2 cell culture incubator. A Neubauer hemacytometer was used to determine the cell number and viability using the trypan blue exclusion method. glucose. HepaRG cells were seeded in Williams' E medium supplemented with 10% fetal calf serum (Thermo scientific, San Jose, USA), 100 U/ml penicillin, 100 lg/ml streptomycin, 5 lg/ml insulin, 2 mM glutamine, and 50 lM hydrocortisone hemisuccinate. After 2 weeks, these undifferentiated cells were transferred to the same medium supplemented with 2% dimethyl sulfoxide (DMSO) and cultured for further 2 weeks in order to obtain cells expressing liver-specific functions. Induction of CYP3A4 or CYP1A2 was achieved by incubation of differentiated HepaRG cells with 20 lM rifampicin or 5 lM 3-methylcholanthrene for 72 h, respectively, with medium change every 24 h (Berger et al., 2016) .
Mouse liver mitochondria. Male C57BL/6 mice were kept in the animal facility of the University Hospital Basel (Basel, Switzerland) in a temperature-controlled environment with a 12-h light/dark cycle and food and water ad libitum. Animal procedures were conducted in accordance with the institutional guidelines for the care and use of laboratory animals. The mean mouse weight was 2562 g and the mean liver weight 1.360.1 g. Mice were sacrificed by cervical dislocation. Fresh liver tissue was quickly removed and immersed in ice-cold isolation buffer (200 mM mannitol, 50 mM sucrose, 1 mM Na 4 EDTA, 20 mM HEPES, pH 7.4) and isolated by differential centrifugation as described previously (Hoppel et al., 1979) . The mitochondrial protein content was determined using the bicinchoninic acid (BCA) protein assay kit from Thermo Scientific (Wohlen, Switzerland).
Cytotoxicity. Cells were seeded at 20 000 cells/well in a 96-well plate 24 h prior drug treatment. We used the ToxiLightV R (Lonza, Basel, Switzerland) assay to determine the cytotoxicity of different concentrations (1, 5, 10, 20, 50 , and 100 lM) and treatment times (24 and 48 h) of the azoles indicated. We used Triton X 0.1% as a positive control, which destroys cells completely and led to an approximately 10-fold increase in adenylate kinase release. The release of adenylate kinase was measured according to the manufacturer's instructions. Briefly, ToxiLight V R reaction buffer (100 ll) was mixed with 20 ll of supernatant from the treated cells. Then, the mixture was left in the dark for 5 min and the luminescence was measured with a Tecan M200 Pro Infinity plate reader (M€ annedorf, Switzerland).
Intracellular ATP content. Cells were seeded at 20 000 cells/well in a 96-well plate. HepG2 cells were then treated with azoles at different concentrations (1, 5, 10, 20, 50 , and 100 lM) and incubation times (24 and 48 h). We used Triton X 0.1% as a positive control, which destroys cells and depletes the intracellular ATP content completely. Intracellular ATP was determined using the CellTiterGlo Luminescent cell viability assay (Promega, Switzerland), in accordance with the manufacturer's instructions. Briefly, 100 ll of assay buffer was added to each 96-well containing 100 ll culture medium. After incubation in the dark for 12 min, luminescence was measured using a Tecan M200 Pro Infinity plate reader.
Mitochondrial membrane potential in cells and isolated liver mitochondria. HepG2 cells were seeded in a 12-well plate at 500 000 cells/well 24 h prior exposure to azoles at the concentrations indicated. The mitochondrial membrane potential was assessed using the fluorescent cationic dye TMRM from Life Technologies (Zug, Switzerland). First, cells were trypsinized after the indicated incubation time and the cell pellet resuspended in DPBS. TMRM was dissolved in DMSO, and added to resuspended cells at a final concentration of 50 nM. Cells were incubated on a shaker at 37 C for 20 min in the dark.
Afterwards, cells were centrifuged and the pellet resuspended in DPBS. Samples were measured by flow cytometry (BD FACSCalibur TM , Becton Dickinson AG, Allschwil, Switzerland) on the FL2-H channel. FCCP (10 lM) was added to control cells and served as positive control. Data were analyzed using CellQuest Pro software (BD Bioscience, Allschwil, Switzerland). The mitochondrial membrane potential in isolated mouse liver mitochondria was determined as described by Kaufmann et al. (2005) with some modifications. Freshly isolated mouse liver mitochondria were washed with incubation buffer containing 137 mM sodium chloride, 4.74 mM potassium chloride, 2.56 mM calcium chloride, 1.18 mM potassium phosphate, 1.18 mM magnesium chloride, 10 mM HEPES, and 1 g/l glucose (pH 7.4). Then, mitochondria were incubated at 37 C in incubation buffer containing 0.5 ll/ml [phenyl-3 H]-tetraphenylphosphonium bromide ( 3 H-TPP; 40 Ci/mmol, Anawa trading SA, Wangen, Switzerland). After 15 min, the suspension was centrifuged and the mitochondrial pellet resuspended in fresh nonradioactive incubation buffer. Afterwards, mitochondria were treated with drugs at concentrations indicated for 15 min at 37 C and centrifuged. After the incubation, radioactivity of the mitochondrial pellet was measured on a Packard 1900 TR liquid scintillation analyzer.
Activities of the enzyme complexes of the mitochondrial electron transport chain in permeabilized cells and isolated mouse liver mitochondria. The activity of specific enzyme complexes of the respiratory chain was analyzed using an Oxygraph-2k high-resolution respirometer equipped with DatLab software (Oroboros Instruments, Innsbruck, Austria). HepG2 cells were seeded in T75 cell culture flasks and treated for 24 h with ketoconazole or posaconazole at the concentrations and periods of time indicated in the Result section. Then, the trypsinized HepG2 cells or freshly isolated mouse liver mitochondria were resuspended in MiR06 (mitochondrial respiration medium containing 0.5 mM EGTA, 3 mM MgCl 2 , 60 mM K-lactobionate, 20 mM taurine, 10 mM KH 2 PO 4 , 20 mM HEPES, 110 mM sucrose, 1 g/l fatty acidfree bovine serum albumin (BSA), and 280 U/ml catalase, pH 7.1) before being transferred to the pre-calibrated oxygraph chambers. The activities of complexes I, II, III, and IV were assessed in fresh mouse liver mitochondria and HepG2 cells permeabilized with digitonin (10 lg/1 million cells). In a first run, complexes I and III were analyzed using L-glutamate/malate (10 and 5 mM, respectively) as substrates followed by the addition of ADP (2 mM). Then, the oxidative leak, a marker for uncoupling, was identified by the assessment of the residual oxygen consumption after addition of oligomycin (1 lM). We elucidated the uncoupling capacity with the addition of FCCP (1 lM) followed by inhibition of complex I with rotenone (0.5 lM). Afterwards, duroquinol (500 lM, Tokyo Chemical Industry, Tokyo, Japan) was added to investigate complex III and inhibited with antimycin A (2.5 lM). In a second run, complexes II and IV were analyzed using succinate (10 mM) as substrate in the presence of rotenone (0.5 lM) to block complex I. This was followed by the addition of ADP (2 mM). Again, the oxidative leak was identified by the assessment of the residual oxygen consumption after addition of oligomycin (1 lM), followed by the addition of FCCP (1 lM) in order to evaluate the uncoupling capacity. After this, the inhibitor antimycin A (2.5 lM) was added to block complex III. Subsequently, N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD)/ascorbate (0.5 and 2 mM, respectively) were added to investigate complex IV followed by an inhibition of this complex with KCN (1 mM). To assure the integrity of the outer mitochondrial membrane, the absence of a stimulatory effect of exogenous cytochrome c (10 mM) on respiration was shown. We used the Pierce bicinchoninic acid protein assay kit from Thermo Scientific (Darmstadt, Germany) to determine the protein concentrations. Respiration rates are expressed in picomoles O 2 per second per mg protein.
Mitochondrial superoxide anion accumulation. Mitochondrial superoxide anion production was determined with the fluorogenic dye MitoSOX TM Red reagent (Molecular Probes, Eugene, OR, U.S.A.). Cells were seeded at 25,000 cells/well in a 96-well plate.
After 24 h of treatment with azoles at the concentrations indicated, the medium was removed and the HepG2 cells stained with MitoSOX red (dissolved in DPBS) at a final concentration of 2 lM. We used amiodarone 50 lM as a positive control. The plate was incubated in the dark at 37 C for 15 min, afterwards fluorescence was measured at an excitation wavelength of 510 nm and an emission wavelength of 580 nm using a Tecan Infinite pro 200 microplate reader. We normalized the results to the protein content using the Pierce BCA Protein Assay Kit (Darmstadt, Germany) according to manufacturer's instruction.
Quantitative RT-PCR. Cells were seeded in 12-well plates 24 h prior treatment. After 24 h of incubation with the compounds indicated, cells were lysed with 350 ml of RLT buffer (Qiagen, Hombrechtikon, Switzerland) and the cell lysate was transferred to Qiashredder columns and centrifuged for 2 min at 13 000 rpm. From the eluate, total RNA was extracted according to the manufacturer's protocol (Qiagen RNeasy Mini Extraction kit). We assessed the RNA quality with a NanoDrop 2000 (Thermo Scientific, Wohlen, Switzerland). The Qiagen Omniscript system was used to reversely transcribe the isolated RNA (1 lg) to cDNA. The expression of mRNA was evaluated using SYBR Green real-time PCR (Roche Diagnostics, Rotkreuz, Basel). Real-time RT-PCR was performed in triplicate on an ABI PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzerland) and quantification was carried out using the comparative-threshold cycle method. Forward and reverse primers for genes of interest and GAPDH as endogenous reference control (see Table 1 for primers) were purchased from Microsynth (Balgach, Switzerland).
Protein extraction and Western blot analysis. Cells were seeded in 6-well plates at 10 6 cells per well, 24 h prior treatment with ketoconazole and posaconazole. After 24 h of incubation with the compounds indicated, cells were washed with ice-cold PBS and lysed with RIPA buffer (50 nM Tris-HCL, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 1 mM EDTA in water). Lysates were incubated with RIPA buffer under constant agitation for 20 min and then centrifuged at 13 000 rpm for 10 min at 4 C. Mitochondrial DNA content. As a measure of the mitochondrial DNA content, we determined the ratio of the DNA content of the mitochondrial gene ND1 and the nuclear gene 36B4 (see Table 1 for primers) using quantitative real-time RT-PCR as described with some modifications (Pieters et al., 2013) . Total DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hombrechtikon, Switzerland) following the manufacturer's instructions. The concentration of the extracted DNA was measured spectrophotometrically at 260 nm with the NanoDrop 2000 (Thermo Scientific, Wohlen, Switzerland). Afterwards, DNA was diluted in RNase free water to a final concentration of 10 ng/ll. The expression of the mitochondrial and nuclear genes was evaluated using SYBR Green real-time PCR (Roche Diagnostics, Rotkreuz, Basel) and was performed on an ABI PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzerland). Quantification was performed using the comparative-threshold cycle method.
Statistical methods. Data are given as the mean 6 standard deviation (SD) of at least 3 independent experiments. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, US). One-way analysis of variance (ANOVA) was used for comparisons of more than 2 groups, followed by Dunnett's post-test procedure to localize differences between the individual groups tested. Non-parametric tests Nrf-2  AGC CCA GCA CAT CCA GTC AG  TGC ATG CAG TCA TCA AAG TAC AAA G  SOD2  GGT TGT TCA CGT AGG CCG  CAG CAG GCA GCT GGC T  GAPDH  TGG TAT CGT GGA AGG ACT CA  GGG CCA TCG ACA GTC TTC  ND-1  ATG GCC AAC CTC CTA CTC CT  CTA CAA CGT TGG GGC CTT T  36B4 GGA ATG TGG GCT TTG TGT TC CCC AAT TGT CCC CTT ACC TT Bax GGG GAC GAA CTG GAC AGT AA CAG TTG AAG TTG CCG TCA GA Bcl-2 CTG CAC CTG ACG CCC TTC ACC CAC ATG ACC CCA CCG AAC TCA AAG A CYP3A4
GAT GGC TCT CAT CCC AGA CTT AGT CCA TGT GAA TGG GTT CC CYP1A2 GTC ATT GGT GCC ATG TGC T GCT GAG CAT CTC ATC GCT ACT were used in case of not normally distributed data. P-values < .05 were considered as significant.
RESULTS

Cytotoxicity and Intracellular ATP Content in Azole-Treated HepG2 Cells
To elucidate the toxic effects of the four investigated azoles (ketoconazole, posaconazole, fluconazole, and voriconazole), we first assessed cytotoxicity and cellular ATP content in HepG2 cells exposed at different concentrations for two time periods (24 and 48 h).
As expected, Triton X 0.1% showed an increase of adenylate kinase and a depletion of ATP content. After 24 h of exposure, we found an increase in adenylate kinase release in ketoconazole and posaconazole treated HepG2 cells starting from 50 and 20 mM respectively, whereas fluconazole or voriconazole were not cytotoxic up to 100 mM (Figure 2A) . In comparison to cytotoxicity, the intracellular ATP content of HepG2 cells started to decrease at a lower concentration, namely at 10 mM in the presence of ketoconazole or posaconazole. Similar to cytotoxicity, fluconazole and voriconazole did not affect the ATP content of HepG2 cells up to 100 mM ( Figure 2B) .
After 48 h of exposure, fluconazole and voriconazole were not cytotoxic and did not decrease the cellular ATP content up to a concentration of 100 mM (Figs. 2C and D) . In comparison, both ketoconazole and posaconazole were cytotoxic (posaconazole at 10 mM and ketoconazole at 10 mM) and they started to decrease the ATP content already at lower concentrations (posaconazole at 5 mM and ketoconazole at 10 mM).
In order to find out, if metabolites could be responsible for the observed cytotoxicity, we conducted cytotoxicity studies in HepaRG cells under basal conditions and after induction of CYP3A4 or CYP1A2 with rifampicin or 3-methylcholanthrene, respectively. As expected, treatment for 72 h with rifampicin or 3-methylcholanthrene was associated with a significant increase in CYP3A4 or CYP1A2 mRNA expression, respectively ( Supplementary Figs. S1A and B) . Fluconazole or voriconazole were not cytotoxic up to 100 mM irrespective of pretreatment with rifampicin or 3-methylcholanthrene (Figs. 3C , D, G, and H).
In non-induced HepaRG cells, ketoconazole and posaconazole started to show cytotoxicity at 100 and 20 mM, respectively (Figs. 3A, B, E, and F). CYP induction by rifampicin or 3-methylcholanthrene slightly accentuated cytotoxicity for both ketoconazole and posaconazole, suggesting that metabolites formed by CYP3A4 and CYP1A2 could contribute to cytotoxicity. Triton X 0.1%, which was used as a positive control, showed an increase of adenylate kinase and a depletion of ATP content. Considering the only small increase in ketoconazole and posaconazole-associated cytotoxicity with CYP induction, the following studies were carried out with the parent compounds.
Long-Term Effects on Mitochondria in HepG2 Cells
Because the cellular ATP content of HepG2 cells started to drop at clearly lower concentrations than cytotoxicity occurred, we assumed mitochondrial toxicity for posaconazole and ketoconazole (Felser et al., 2013; Kaufmann et al., 2005) and investigated the effect of the azoles on mitochondrial function.
The mitochondrial membrane potential (Dw m ) reflects the electrical potential across the inner mitochondrial membrane, which is mainly generated by the proton gradient between the mitochondrial matrix and the intermembrane space. Mitochondrial toxicants are expected to be associated with a decrease Dw m , which can therefore be used as a marker of mitochondrial function and integrity (Felser et al., 2013; Kaufmann et al., 2005) .
In HepG2 cells exposed for 24 h, posaconazole decreased Dw m in a dose-dependent manner starting at 10 mM, whereas ketoconazole decreased Dw m already at 5 mM. However, we did not find any changes in Dw m in incubations with fluconazole or voriconazole ( Figure 4A ).
In support of these data, ketoconazole significantly reduced the activities of all enzyme complexes starting at 20 mM (complex III) or 50 mM (complex I, II, and IV) in HepG2 cells treated for 24 h ( Figure 4B ). Under the same conditions, posaconazole reduced complex III starting at 20 mM and complex I activity at 50 mM ( Figure 4C ). These results confirmed mitochondrial toxicity of ketoconazole and posaconazole and the lack of cytotoxicity of voriconazole and fluconazole.
Effect on Mitochondrial DNA Because a decrease in mtDNA can be associated with impaired mitochondrial protein synthesis and therefore impaired activity of complexes I, III, and/or IV (Jiang et al., 2013), we investigated the mtDNA/nuclear DNA ratio. As shown in Figure 5A , 24 h of treatment with ketoconazole or posaconazole was associated with a decrease in the mtDNA/nuclear DNA ratio starting at 10 mM.
Acute Exposure on Isolated Mouse Liver Mitochondria
Acute exposure (15 min) of freshly isolated mouse liver mitochondria with ketoconazole resulted in a 30% decrease in Dw m starting at 5 mM, whereas posaconazole did not affect Dw m under these conditions ( Figure 5B ). These results were confirmed in acutely exposed liver mitochondria, where ketoconazole inhibited complex I starting at 20 mM, but did not affect the activity of the other enzyme complexes of the electron transport chain ( Figure 5C ). The impairment observed in HepG2 cells after 24 h exposure on the enzyme complexes of the respiratory chain can therefore be explained by a direct and acute toxic effect of the azoles and a long-term effect for which inhibition of mitochondrial DNA synthesis may be at least a contributing factor.
Superoxide Anion Accumulation
As complexes I and III of the electron transport chain are the main sites of mitochondrial superoxide anion generation (Balaban et al., 2005) , we examined the accumulation of superoxide anion in HepG2 cells exposed to azoles for 24 h. Amiodarone at 50 mM, which was used as a positive control, was associated with a 6-fold increase in superoxide anion (data not shown). We found a significantly increased superoxide accumulation when cells were treated with ketoconazole or posaconazole, but not with voriconazole or fluconazole. Exposure with ketoconazole was associated with a 1.5-to 2-fold increase in superoxide accumulation at concentrations from 20 to 100 mM. With posaconazole, superoxide accumulation increased 3-fold compared with control conditions between 10 and 100 mM ( Figure 6A ).
Nrf-2 (nuclear factor-E2-related factor-2) is activated by ROS and regulates the expression of many cytoprotective enzymes involved in the cellular antioxidative defense system, which results in cellular protection against ROS (Copple et al., 2008) . SOD2 (superoxide dismutase 2) is a mitochondrial enzyme involved in superoxide anion degradation (Felser et al., 2013) . As shown in Figures 6B and C , both 20 mM ketoconazole and 50 mM posaconazole significantly increased the mRNA expression of Nrf-2 and SOD2, indicating activation of the antioxidative defense system.
Mechanisms of Cell Death in HepG2 Cells
When oxidative stress overcomes the cellular defense mechanisms, it starts to damage proteins, lipids and DNA and can induce apoptosis (Roberts et al., 2010) . In order to find out whether HepG2 cell death associated with ketoconazole and posaconazole is induced by apoptosis, we examined the protein expression of key mediators of apoptosis. In order to show the potential implication of the mitochondrial pathway of apoptosis, we studied the gene expression of Bax and Bcl-2 at the mRNA level in HepG2 cells. The ratio between the pro-apoptotic Bax and the anti-apoptotic Bcl-2, which is considered to be a trigger for apoptosis, increased in a concentration-dependent manner in ketoconazole and posaconazole treated HepG2 cells, starting at 20 mM ( Figure 7A ). As shown in figure 7B , exposure with ketoconazole and posaconazole for 24h was associated with concentration-dependent increases of cleaved caspase 9 ( Figure 7C ), cleaved caspase 3 ( Figure 7D ) and cleaved Poly(ADPribose)-Polymerase (PARP) ( Figure 7E ). Caspase 9 is an initiator caspase which binds to and is activated by the caspaseactivating complex Apaf-1 (Cain, 2003) . The activated caspase 9 cleaves and activates the executioner caspase 3, which initiates the execution phase of apoptosis. PARP 1 is an enzyme involved in DNA reparation processes and is cleaved by caspase 3 during apoptosis (Soldani and Scovassi, 2002) . Activation of caspase 9 and caspase 3 and cleavage of PARP therefore prove initiation of apoptosis. The activation of caspase 3 and 9 at similar concentrations as the accumulation of ROS (see Figure 6A ) supports the concept that cellular accumulation of ROS is associated with initiation of apoptosis (Redza-Dutordoir and Averill-Bates, 2016).
Cytotoxicity in HepG2 Cells With Mitochondrial Dysfunction
The current toxicological characterization revealed a mitochondrially-mediated toxicity of ketoconazole and posaconazole starting at 5-10 mM, but not of fluconazole or voriconazole up to 100 mM. In order to test the hypothesis that a preexisting mitochondrial deficiency renders cells more susceptible to mitochondrial toxicants, we investigated ketoconazole and posaconazole on a previously established system of mitochondrial dysfunction (Haegler et al., 2015) . First, we pre-treated HepG2 cells with non-toxic concentrations of the vitamin B12 analog HCCL or the combination of HCCL and propionic acid 
DISCUSSION
Our investigations revealed that two of the four azoles investigated, the imidazole ketoconazole and the most newly launched triazole posaconazole, are potent inhibitors of important mitochondrial functions. Exposure of HepG2 cells with these azoles was associated with decreased mitochondrial membrane potential, impaired function of the mitochondrial electron transport chain, impaired synthesis of mitochondrial DNA, increased mitochondrial oxidative stress with activation of the antioxidant system and apoptosis. In comparison, fluconazole and voriconazole were not toxic up to 100 lM in both human hepatoma cell lines used. In contrast to the findings in the current study, which revealed no cytotoxicity for fluconazole and voriconazole, there are reports of hepatotoxicity in the literature for both compounds (Bronstein et al., 1997; Raschi et al., 2014; Lo Re et al., 2016; Foo and Gottlieb, 2007; Kao et al., 2014) . Fluconazole is mainly eliminated unchanged by the kidneys (Lewis, 2011) , whereas voriconazole undergoes extensive hepatic metabolism by mainly CYP2C19 and CYP3A4, leading to N-oxidation of the pyrimidine ring (Hyland et al., 2003) . Because, rifampicin induces CYP2C19 and CYP3A4 in HepaRG cells (Berger et al., 2016; Gerets et al., 2012) , an increased formation of the voriconazole N-oxide metabolite could have been expected under the conditions used in our experiments. However, cytotoxicity of voriconazole did not increase in HepaRG cells treated with rifampicin or 3-methylcholanthrene, suggesting that voriconazole N-oxide is not responsible for hepatotoxicity associated with voriconazole. This conclusion must be made with caution, however, because we did not determine voriconazole N-oxide and voriconazole itself showed no cytotoxicity in both cell systems used in the current studies. It is possible that our in vitro systems were not suitable to detect hepatocellular toxicity associated with voriconazole and/or its major metabolite voriconazole N-oxide. mitochondrial accumulation of radioactivity was determined. C, Activity of the enzyme complexes of the electron transport chain in freshly isolated mouse liver mitochondria acutely exposed to ketoconazole. Data are shown as mean 6 SD of five independent experiments. *P < .05 versus control incubations containing 0.1% DMSO.
For instance, these systems are not able to detect immunemediated toxicity and it is not entirely clear whether voriconazole could enter HepG2 and HepaRG cells. Our data do agree, however, with a recent study from Somchit et al. (2012) , who observed no relevant hepatic or renal toxicity in rats treated with single (up to 200 mg/kg) or repetitive doses (14 days up to 100 mg/kg) of voriconazole intraperitoneally. Regarding fluconazole, the data of the current study are in agreement with a previous study in which fluconazole up to 1 mM was only marginally cytotoxic for primary rat hepatocytes (Rodriguez and Acosta, 1995) . Because fluconazole is excreted almost entirely unchanged by the kidneys (Lewis, 2011) , it could be expected that CYP induction by rifampicin or 3-methylcholanthrene would not increase fluconazole-associated toxicity in HepaRG cells.
As shown in Figure 2 , posaconazole and ketoconazole were toxic in HepG2 cells. Importantly, the cellular ATP content dropped at lower posaconazole and ketoconazole concentrations than cytotoxicity was detectable, indicating mitochondrial toxicity of these compounds. For ketoconazole, this has been demonstrated in isolated rat liver mitochondria (Rodriguez and Acosta, 1996) . We could not only confirm these data in human cell systems, but could detect potential mechanisms and demonstrate the consequences on cell metabolism and survival.
Regarding ketoconazole, hepatocellular toxicity has been shown for the parent compound (Rodriguez and Acosta, 1995) as well as for the N-deacetylated main metabolite (Rodriguez and Acosta, 1997b) . N-deacetyl-ketoconazole can be N-oxidized at the piperazine ring by flavin-containing monooxygenases (FMO) (Rodriguez and Acosta, 1997a; Rodriguez and Miranda, 2000; Rodriguez et al., 1999) and this N-oxide is considered to be hepatotoxic (Rodriguez and Buckholz, 2003) . In the current study, we used the parent compound, not the N-deacetylated metabolite. Because hydrolases are ubiquitous enzymes, it can be assumed that N-deacetylation occurred in the cell models used by us. In addition, it has recently been shown that FMO1 and FMO3, the most important human enzymes for N-deacetylketoconazole oxidation (Rodriguez and Miranda, 2000) , are functionally expressed in HepG2 cells (Fedejko-Kap et al., 2011) . It is possible that at least some of the toxicity by ketoconazole observed in the current study has been due to the N-oxide of Ndeacetyl-ketoconazole. FMOs are induced via activation of the aryl hydrocarbon receptor (Celius et al., 2008 (Celius et al., , 2010 , which is stimulated by 3-methylcholanthrene and only weakly by rifampicin (Derungs et al., 2015) . This may be reflected by the at least numerical increase in cytotoxicity in HepaRG cells pretreated with 3-methylcholanthrene compared with untreated HepaRG cells at the highest ketoconazole concentration (Figure 3) . As shown recently, a substantial portion of ketoconazole is also metabolized by CYP3A4 (Fitch et al., 2009) , which is highly induced by rifampicin in HepaRG cells (Berger et al., 2016; Gerets et al., 2012) . Our data therefore suggest that both CYP3A4 and FMO-associated and metabolites of ketoconazole may be cytotoxic in HepaRG cells.
The concentration-dependent hepatocellular toxicity of posaconazole is an important finding of our study. As suggested by increased cytotoxicity in HepaRG cells pretreated with rifampicin or 3-methlycholanthrene, posaconazole metabolites may also be toxic (Figure 3) . Posaconazole has been associated with liver injury in patients (Lo Re et al., 2016; Raschi et al., 2014) , but there are fewer reports in the literature than for ketoconazole or voriconazole. In the current study, posaconazole decreased the cellular ATP content and the mitochondrial membrane potential in HepG2 cells treated for 24 h, impaired the function of complex I and III of the electron transport chain, increased mitochondrial reactive oxygen species (ROS) production and SOD2 mRNA expression and was associated with apoptosis. The Quantitative results are expressed relative to control incubations. Data are presented as mean 6 SD of at least three independent experiments. *P < .05 versus control incubations containing 0.1% DMSO.
increase in mitochondrial ROS production is most likely a consequence of the inhibition of complex I and III of the respiratory chain (Sinha et al., 2013) and a likely reason for SOD2 mRNA induction (Felser et al., 2013) . Because mitochondrial accumulation of ROS is associated with mitochondrial membrane permeability transition (Balaban et al., 2005; Kaufmann et al., 2005) , increased ROS production is also a likely reason for apoptotic cell death observed in HepG2 cells. Our studies revealed potential mechanisms for the decrease in the activity of the enzyme complexes of the electron transport chain. For ketoconazole, which was acutely toxic on isolated mouse liver mitochondria (see Figure 5A and 5B), a direct inhibition of complex I with subsequent stimulation of ROS production, which can further impair the function of the enzyme complexes of the respiratory chain, is a likely mechanism. The observed decrease in mitochondrial DNA, which suggests a reduction of the mitochondrial number, is an additional possible mechanism for the impairment of the activity of the mitochondrial enzyme complexes for both ketoconazole and posaconazole.
Regarding posaconazole, it is interesting to compare the concentrations associated with hepatocellular toxicity with those obtained in patients. The recommended trough serum concentration for prophylaxis in immunocompromised patients is 700 lg/l (approximately 1 lM) and 1000 lg/l in patients with manifest fungal infection (Ashbee et al., 2014) . In a recent study comparing serum steady state serum concentrations in patients ingesting either 600 mg posaconazole as a suspension or 300 mg posaconazole as retarded tablets, average concentrations of 390 lg/l (range 51-1870 lg/l) or 1781 lg/l (range 662-3350 lg/l) for suspension or tablets, respectively, were determined (Cumpston et al., 2015) . In the tablet group, the patient with the highest steady state serum concentration (3350 lg/l, corresponding to approximately 5 lM) developed hepatocellular liver injury. At a concentration of 5 lM, we started to see hepatocellular injury with the drop of ATP (see Figure 2D ). It is evident that comparisons between in vitro investigations with results obtained in vivo are difficult and have to be considered with caution. Nevertheless, the comparison shows that potentially hepatotoxic concentrations can be reached in vivo.
In the publication of Cumpston et al. (2015) mentioned above, a second patient developed liver injury. This patient had a steady state serum concentration of 390 mg/l (approximately 0.6 mM), which is approximately 10 times lower than the lowest concentration at which we started to observe toxicity. This suggests the presence of susceptibility factors for posaconazole-associated hepatotoxicity other than a high exposure in this patient.
For mitochondrial toxicants, mitochondrial dysfunction is considered to be an important susceptibility factor for idiosyncratic toxicity (Krahenbuhl et al., 2000; Li et al., 2015; Stewart et al., 2010) . Idiosyncratic adverse drug reactions are rare and occur at therapeutic drug doses, implying the presence of susceptibility factors in affected patients. Because adverse hepatic drug reactions often affect mitochondrial function, preexisting mitochondrial dysfunction could represent a susceptibility factor. We have shown in previous publications that treatment with HCCL impairs the activity of enzyme complexes of the electron transport chain both in rats in vivo (Krahenbuhl et al., 1991) and in HepG2 cells in vitro (Haegler et al., 2015) . Furthermore, we have shown previously that drugs affecting mitochondria are toxic at lower concentrations in HepG2 cells treated with HCCL than in untreated HepG2 cells (Haegler et al., 2015) . After having demonstrated that ketoconazole and posaconazole are mitochondrial toxicants, it was therefore interesting to investigate these two compounds in HepG2 cells treated with HCCL. Indeed, we could show that pretreatment with HCCL with or without propionate rendered HepG2 cells more sensitive to the toxic effects of posaconazole and ketoconazole. Our results therefore support the hypothesis that certain susceptibility factors, such as preexisting defects in mitochondrial function, can trigger the manifestation of cellular and organ toxicity at drug concentrations which are not toxic in the absence of such factors.
In conclusion, our study confirms the mitochondrial toxicity of ketoconazole in human cell models, reveals potential mechanisms and demonstrates the consequences of this toxicity for mitochondria and hepatocytes. Furthermore, we provide evidence for a similar toxicity associated with posaconazole and show that cytotoxicity is accentuated in a cell model with impaired mitochondrial function. Our studies are relevant for the understanding of the toxicological mechanisms associated with idiosyncratic toxicants.
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